- Study at RCSI
- Student Life
- Schools & Faculties
- Faculty of Medicine & Health Sciences
- School of Medicine
- School of Pharmacy
- School of Physiotherapy
- School of Postgraduate Studies
- School of Nursing & Midwifery
- Academic Departments
- Institute of Leadership
- Health Professions Education Centre (HPEC)
- Simulation
- Student, Academic & Regulatory Affairs
- Faculty of Sports and Exercise Medicine
- Faculty of Nursing & Midwifery
- Faculty of Dentistry
- Faculty of Radiologists
- Alumni
- Surgical Affairs
- Research & Innovation
- Innovation
- Strategic Academic Recruitment Programme
- Research News & Events
- Research Areas
- Principal Investigators
- Research Networks & Centres
- Technology Cores & Research Facilities
- Research Office
- Employment Opportunities
- PhD Projects and Postgraduate Training Opportunities
- Research Ethics
- Technology Transfer Office & Management of Intellectual Property
- Research by Faculty
- Research by Academic Department
- Research by School
- Human Resources Strategy for Researchers (HRS4R)
- About RCSI
- Council
- CEO and Senior Management
- History
- Annual Report
- Contact us and location
- Communications
- Publications
- Venue hire
- No. 26 York Street
- Athena SWAN
- RCSI and the wider community
- Quality Enhancement Office
- Academic Health Centre
- Irish Society of Urology
- Freedom of Information (FOI)
- Faculty of Medicine & Health Sciences Strategy 2013 - 2017
- Medical Validation Ireland
- Eduroam
- RCSI International
Prof. Celine Marmion secures funding from ONXEO to develop new cancer therapeutic
07 July 2016
Professor Celine Marmion (Department of Pharmaceutical & Medicinal Chemistry) recently commenced an industry collaboration with Onxeo S.A., an innovative European company specializing in the development of orphan oncology therapeutics.
This collaborative discovery-stage programme, with an initial cash and auditable in-kind value in excess of €140,000 is focused on developing derivatives of oncology drug belinostat (Beleodaq®), a histone deacetylase (HDAC) inhibitor, to increase the drug’s lifetime, efficacy and stability.
The collaboration builds on Prof. Marmion’s expertise in rational drug design and the synthesis and pharmacological evaluation of metal-based anti-cancer agents.